With an eye toward a review by the Supreme Court, Monsanto is looking to further impair the $20.4 million verdict in the first trial linking its Roundup weedkiller to cancer.
The Bayer-owned company on Tuesday moved for a rehearing before an appellate court, arguing its first ruling misstated key issues and failed to sufficiently reduce damages.
"The opinion contains several misstatements and omissi...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In